The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.

@article{Gran2006ThePI,
  title={The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.},
  author={Bruno Gran and N Tabibzadeh and Abraham Mart{\'i}n and Elvira S. Ventura and Jeffrey H. Ware and Guang Xian Zhang and Jennifer L. Roth Parr and Ann R. Kennedy and Abdolmohamad M. Rostami},
  journal={Multiple sclerosis},
  year={2006},
  volume={12 6},
  pages={688-97}
}
Available treatments for multiple sclerosis (MS) require frequent injections and have significant side effects. Proteases generated during inflammation are involved in the induction of tissue damage during inflammatory demyelination in the central nervous system (CNS). The Bowman-Birk Inhibitor (BBI), a soy-derived protease inhibitor with anti-carcinogenic and anti-inflammatory properties, has been shown to be well tolerated in clinical trials for pre-cancerous conditions, such as oral… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

The status of human trials utilizing Bowman Birk Inhibitor Concentrate from soybeans

  • AR Kennedy
  • In Sugano M ed. Soy in health and disease…
  • 2005
3 Excerpts

Similar Papers

Loading similar papers…